Loading stock data…
OCC
$11.00+0.70 (+6.80%)
Market ClosedLast close May 1
Optical Cable Corporation, together with its subsidiaries, manufactures and sells fiber optic and copper data communications cabling and connectivity solutions primarily for the enterprise market in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Optical Cable Corporation in the Technology sector is trading at $11.00. The stock is currently 21% below its 52-week high of $13.95, remaining 53.2% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why OCC maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
AAPLMSFTGOOGL
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$11.00
Potential Upside
5%
Whystock Fair Value$11.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Optical Cable Corporation, together with its subsidiaries, manufactures and sells fiber optic and copper data communications cabling and connectivity solutions primarily for the enterprise market in the United States and internationally. The company ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$115.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.64%
Volume
Today's trading volume
307,956
Recent News
Orthocell flags strong March quarter as US Remplir rollout gathers pace
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has reported a solid March 2026 quarter, highlighted by $3.2 million in revenue, growing US traction for nerve repair product Remplir and a cash position of $48 million as the company advances commercial expansion across multiple markets. Revenue for the...
Orthocell completes first Remplir case in US military hospital network
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has moved beyond market access and into active clinical use within the US military and veteran healthcare system, completing the first surgical case using its Remplir nerve repair product in a Department of Defense facility shortly after securing network-wide...
Orthocell secures access to US military and veterans hospital network for Remplir
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has secured a significant expansion of its US market opportunity, gaining approval for its Remplir nerve repair device to be used across the US Department of Defense (DoD) and Veterans Affairs (VA) hospital networks. The approval opens the door to 221...
Orthocell to release March quarterly results, host investor webinar on April 20
Orthocell Ltd (ASX:OCC, OTC:ORHHF) will release its quarterly results for the period ended March 31, 2026, on Monday, April 20, and host an investor webinar the same day. The webinar will cover its quarterly results and provide an operational update, including progress on the US rollout of...
Remplir expected to avoid proposed US pharmaceutical tariffs
Orthocell Ltd (ASX:OCC, OTC:ORHHF)'s flagship Remplir™ product is not expected to be caught by proposed US tariffs on certain pharmaceutical imports, following an announcement by the US Administration on April 2, 2026. The regenerative medicine company said an initial review indicated...